Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 2Other solid neoplasm 2Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Lung Neoplasms 3642Carcinoma, Non-Small-Cell Lung 3583Small Cell Lung Carcinoma 576Breast Neoplasms 419Neoplasms 299Adenocarcinoma of Lung 248Colorectal Neoplasms 222Melanoma 201Mesothelioma, Malignant 183Pancreatic Neoplasms 179Prostatic Neoplasms 178Brain Neoplasms 178Head and Neck Neoplasms 172Neoplasm Metastasis 167Ovarian Neoplasms 153Esophageal Neoplasms 152Mesothelioma 145Colonic Neoplasms 140Stomach Neoplasms 139NSCLC 115Pleural Effusion, Malignant 114Carcinoma, Renal Cell 109Urinary Bladder Neoplasms 105Disease 96Sarcoma 85Uterine Cervical Neoplasms 82Thymoma 79Liver Neoplasms 77Motor Activity 75Squamous Cell Carcinoma of Head and Neck 72

Interventions

irinotecan sucrosofate 1atezolizumab 1Immunoglobulin G 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma, Mucinous × Thoracic × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT04088786 2022-05-06

Phase I Trial HIPEC With Nal-irinotecan

Stony Brook University

Phase 1 Completed
18 enrolled
GastrointestinalOther solid neoplasmThoracic

Adenocarcinoma, Mucinous, Mesothelioma, Pseudomyxoma Peritonei, Stomach Neoplasms, Colorectal Neoplasms, Neoplasms, Cystic, Mucinous, and Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡